This suggests that KCDEGs are directly or indirectly involved in the activation process of CAFs and affect the response to immunotherapy in melanoma patients, which is consistent with our previous conclusion that CAFs-related genes can serve as a predictive marker panel of response to anti-PD-1 therapy. Here, PDCD1 is linked to melanoma.